Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease—Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases-Reference-Cited by-同舟云学术

Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease—Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases

Published:2015-09 Issue:9 Volume:14 Page:769-773
ISSN:1568-9972
Container-title:Autoimmunity Reviews
language:en
Short-container-title:Autoimmunity Reviews

Author:

Azevedo Valderílio Feijó,de Souza Meirelles Eduardo,Kochen Jussara de Almeida Lima,Medeiros Ana Cristina,Miszputen Sender J.,Teixeira Fábio Vieira,Damião Adérson Osmar Mourão Cintra,Kotze Paulo Gustavo,Romiti Ricardo,Arnone Marcelo,Ferreira Magalhães Renata,Maia Cláudia Pires Amaral,de Carvalho André Vicente E.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference44 articles.

1. Developing the nation's biosimilars program;Kozlowski;N Engl J Med,2011

3. Biosimilars: current status and future directions;Roger;Expert Opin Biol Ther,2010

4. Biosimilars—science, status, and strategic perspective;Kresse;Eur J Pharm Biopharm,2009

5. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis;Wiens;Pharmacotherapy,2010

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS?;Arquivos de Gastroenterologia;2024

3. Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study;Frontiers in Pediatrics;2022-10-10

4. Introductory Chapter: Biosimilars - A Regulatory and Clinical Perspective;Biosimilars;2022-06-08